TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11840030

Group type: EXPERIMENTAL
Intervention: Soy formula with added nucleotides
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Soy formula without added nucleotides
Number of subjects: 267

Group type: COMPARATOR
Intervention: Human milk/formula
Number of subjects: 267
Study: 9709767

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 220

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 220
Study: 8018638

Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 200 mg of mifepristone and Placebo
Number of subjects: 32
Study: 2521997

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31530570

Group type: EXPERIMENTAL
Intervention: Prototype child restraint instructional materials
Number of subjects: 44

Group type: COMPARATOR
Intervention: Existing instructional materials for the same restraint (Control)
Number of subjects: 44
Study: 30320503

Group type: EXPERIMENTAL
Intervention: Oral Antidiabetic Drugs (OAD)
Number of subjects: 434629

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 434629
Study: 26972358

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dressing (Healoderm)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional dressing material
Number of subjects: 34
Study: 24716681

Group type: EXPERIMENTAL
Intervention: Tenecteplase plus heparin
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo plus heparin
Number of subjects: 1006
Study: 22425308

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone graft (BPTB)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Single-bundle hamstring graft (HT-SB)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Double-bundle hamstring graft (HT-DB)
Number of subjects: 62

Group type: COMPARATOR
Intervention: All groups (BPTB, HT-SB, HT-DB)
Number of subjects: 62
Study: 20574538

Group type: EXPERIMENTAL
Intervention: SP plus amodiaquine (AQ)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: DHA plus piperaquine (PQ)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: SP plus piperaquine (PQ)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Control group (age matched children)
Number of subjects: 1008
Study: 18079051

Group type: EXPERIMENTAL
Intervention: Repeat PSA test
Number of subjects: 4102
Study: 15677608

Group type: EXPERIMENTAL
Intervention: Selegiline augmentation of antipsychotic medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 13679527

Group type: EXPERIMENTAL
Intervention: High-intensity warfarin (INR 3.1 to 4.0)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Moderate-intensity warfarin (INR 2.0 to 3.0)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: High-intensity warfarin
Number of subjects: 114

Group type: COMPARATOR
Intervention: Moderate-intensity warfarin
Number of subjects: 114
Study: 11423583

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 8994481

Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 7957469

Group type: EXPERIMENTAL
Intervention: Bone marrow immunoscintigraphy using a 99mTc‐labelled anti‐NCA‐95 monoclonal antibody
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional bone scintigraphy with 99mTc‐methylene‐diphosphonate
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bone marrow immunoscintigraphy
Number of subjects: 58
Study: 2887726

Group type: EXPERIMENTAL
Intervention: Yohimbine (18 mg a day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Yohimbine (after placebo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Yohimbine overall
Number of subjects: 48
Study: 2234996

Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4599852

Group type: EXPERIMENTAL
Intervention: Experimental group (integration of nonretarded children and EMR adolescents)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (not integrated)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Female subjects in all groups
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Male subjects in all groups
Number of subjects: 400
Study: 30922733

Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 twice daily on days 1–14 of a 21-day cycle, for eight cycles)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 447
Study: 28554599

Group type: EXPERIMENTAL
Intervention: CAM2038 q1w (7.5, 15, 22.5, and 30mg doses)
Number of subjects: 0
Study: 25832034

Group type: EXPERIMENTAL
Intervention: Transapical TAVR (TA-TAVR)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Transfemoral TAVR (TF-TAVR)
Number of subjects: 501
Study: 22945837

Group type: EXPERIMENTAL
Intervention: Laparoscopic pectopexy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Laparoscopic sacral colpopexy
Number of subjects: 83
Study: 21253394

Group type: EXPERIMENTAL
Intervention: Quick test (Biohit Plc, Helsinki, Finland)
Number of subjects: 185

Group type: COMPARATOR
Intervention: CLO test (Kimberly‐Clark, Utah, USA)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Quick test
Number of subjects: 185

Group type: COMPARATOR
Intervention: CLO test
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Switching to Quick test
Number of subjects: 185
Study: 18854973

Group type: EXPERIMENTAL
Intervention: Cephalic mask
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 34
Study: 17276529

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 143

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 143
Study: 15554568

Group type: EXPERIMENTAL
Intervention: Methylphenidate (titrated from 0.5 mg/kg per day in week 1 to 1.0 mg/kg per day in week 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 45
Study: 11483834

Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine (1 or 2 doses)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine
Number of subjects: 1602
Study: 9663731

Group type: EXPERIMENTAL
Intervention: Psyllium (5.1 g b.d.)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Docusate sodium (100 mg b.d.)
Number of subjects: 170
Study: 8164599

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Antacid (40 mmol/day)
Number of subjects: 686
Study: 3257375

Group type: EXPERIMENTAL
Intervention: Cefamandole 15 mg/kg administered intravenously shortly before cannulation (Group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefamandole 30 mg/kg administered intravenously during induction of anesthesia (Group 1)
Number of subjects: 0
Study: 31748467

Group type: EXPERIMENTAL
Intervention: 420 mg evolocumab every 4 weeks (Q4W)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 140 mg evolocumab every 2 weeks (Q2W)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 10 mg ezetimibe daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: SC placebo Q4W
Number of subjects: 61

Group type: COMPARATOR
Intervention: SC placebo Q2W
Number of subjects: 61
Study: 30972995

Group type: EXPERIMENTAL
Intervention: CSII combined with sitagliptin treatment (group C)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CSII combined with acarbose treatment (group B)
Number of subjects: 103

Group type: COMPARATOR
Intervention: CSII treatment alone (group A)
Number of subjects: 103
Study: 28355090

Group type: EXPERIMENTAL
Intervention: TX-004HR (4-μg, 10-μg, and 25-μg doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26344671

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) treatment, intravenous, open-label, assessed over the first 4 months (5 infusions).
Number of subjects: 610
Study: 23537344

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual Care (CTRL)
Number of subjects: 48
Study: 21761206

Group type: EXPERIMENTAL
Intervention: Electrical stimulation using P6 acupoint for 30 min before spinal anesthesia (group III; n=150)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron 30 min before spinal anesthesia (group II; n=150)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo (group I; n=150)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Active treatment groups (II, III)
Number of subjects: 450
Study: 18484458

Group type: EXPERIMENTAL
Intervention: Computer-based session (40 minutes)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Lecture-based session (40 minutes)
Number of subjects: 179
Study: 16488926

Group type: EXPERIMENTAL
Intervention: Post-extraction time groups (10 s to 60 min)
Number of subjects: 500
Study: 14966631

Group type: EXPERIMENTAL
Intervention: Metronidazole-chlorhexidine solution
Number of subjects: 202

Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 202
Study: 10798468

Group type: EXPERIMENTAL
Intervention: Instruction in the detection and management of urinary incontinence, educational materials for providers and patients, office system supports, and academic detailing.
Number of subjects: 668

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 668
Study: 8636175

Group type: EXPERIMENTAL
Intervention: Open reduction and bone grafting
Number of subjects: 120

Group type: COMPARATOR
Intervention: Remanipulation and plaster
Number of subjects: 120

Group type: COMPARATOR
Intervention: Closed external fixation with mobilisation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Closed external fixation without mobilisation
Number of subjects: 120
Study: 1318281

Group type: EXPERIMENTAL
Intervention: ephedrine/caffeine combination (20mg/200mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: ephedrine (20 mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: caffeine (200 mg)
Number of subjects: 180
Study: 6469401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Basal test
Number of subjects: 103
Study: 31331803

Group type: EXPERIMENTAL
Intervention: Guided imagery applied perioperatively (once preoperatively, once on the first postoperative day, twice on the second and third days, totaling six applications)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided imagery applied perioperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment and nursing care
Number of subjects: 0
Study: 29870922

Group type: EXPERIMENTAL
Intervention: Capacitive-resistive electric transfer therapy (Tecar)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive rest (Control)
Number of subjects: 14
Study: 26963316

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 0
Study: 25130297

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg IV for 5 days
Number of subjects: 241

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg IV for 7-14 days
Number of subjects: 241
Study: 22443460

Group type: EXPERIMENTAL
Intervention: PCI at hospitals without on-site cardiac surgery
Number of subjects: 18867

Group type: COMPARATOR
Intervention: PCI at hospitals with on-site cardiac surgery
Number of subjects: 18867
Study: 21218756

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 380
Study: 18669898

Group type: EXPERIMENTAL
Intervention: Endovascular coiling (EVT)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Neurosurgical clipping (NST)
Number of subjects: 278
Study: 15899100

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg od
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg od with loading dose of 200 mg od for the first two weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg od
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11840406

Group type: EXPERIMENTAL
Intervention: Preoperative exercise (strength activities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anesthesia or analgesia
Number of subjects: 0
Study: 10086760

Group type: EXPERIMENTAL
Intervention: Collaborative treatment by primary care physicians (PCPs) and mental health providers (MHPs)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Contact with co-treating MHPs
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Co-location of MHP and PCP practices
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Managed care programs
Number of subjects: 162
Study: 7670605

Group type: EXPERIMENTAL
Intervention: Hollister Colostomy Adhesive with Silastic Medical Adhesive A
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hollister Colostomy Adhesive with Silastic MDX 4‐4210
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pros‐Aide Adhesive with Silastic MDX 4‐4210
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pros‐Aide Adhesive with Silicone A‐2186
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pros‐Aide Adhesive with Silastic Medical Adhesive A
Number of subjects: 25
Study: 2124982

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 10
Study: 383417

Group type: EXPERIMENTAL
Intervention: PEEP therapy (10 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No PEEP (14 patients)
Number of subjects: 24
Study: 30963555

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia
Number of subjects: 11208

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 11208

Group type: COMPARATOR
Intervention: Volatile anaesthesia
Number of subjects: 11208

Group type: COMPARATOR
Intervention: Paravertebral analgesia
Number of subjects: 11208
Study: 29911826

Group type: EXPERIMENTAL
Intervention: Supportive information (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supportive information (Group B)
Number of subjects: 0
Study: 26140739

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/dL)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 23823904

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Awareness of OCR
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Marital status (married)
Number of subjects: 181
Study: 21134995

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy (20 mg/day, group Ia, n = 15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypolipidemic diet therapy (group Ib, n = 15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normolipidemic patients (group II, n = 30)
Number of subjects: 60
Study: 19034106

Group type: EXPERIMENTAL
Intervention: Tariquidar (150 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 16310974

Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (CM)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Post-treatment motivation
Number of subjects: 115
Study: 12749496

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational activities prior to distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community perceptions about ITNs
Number of subjects: 0
Study: 10938184

Group type: EXPERIMENTAL
Intervention: Hydroquinidine (450 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1590680

Group type: EXPERIMENTAL
Intervention: Cefprozil (500 mg every 12 h for 8 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3844036

Group type: EXPERIMENTAL
Intervention: Repeated 3-g doses of amoxycillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single 3-g dose of amoxycillin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 30706097

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH, 20 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30264159

Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) administered before and 24 hours after PCI.
Number of subjects: 4191

Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) administered less than 12 hours before PCI.
Number of subjects: 4191

Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) in patients with ST-segment elevation myocardial infarction (STEMI).
Number of subjects: 4191

Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) in patients with non-ST-segment elevation ACS.
Number of subjects: 4191
Study: 27145825

Group type: EXPERIMENTAL
Intervention: Carvedilol + ivabradine (group II)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Carvedilol only (group I)
Number of subjects: 100
Study: 23735746

Group type: EXPERIMENTAL
Intervention: Golimumab 200 mg/100 mg
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab 400 mg/200 mg
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1064
Study: 22188546

Group type: EXPERIMENTAL
Intervention: Affectively hot condition (blood donation paraphernalia)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cold condition (control)
Number of subjects: 76
Study: 19732237

Group type: COMPARATOR
Intervention: Pulmonary vein antrum isolation (PVAI) only
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI) and superior vena cava isolation (SVCI)
Number of subjects: 320
Study: 18614871

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine (sdNVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine (ZDV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination ZDV/sdNVP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-course highly active antiretroviral therapy (HAART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 0
Study: 16143787

Group type: EXPERIMENTAL
Intervention: IMCBT plus 3DCRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 0
Study: 12171813

Group type: EXPERIMENTAL
Intervention: Lowest quartile of emotional scale scores on the SOLDQ
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Lowest quartile of physical scale scores on the SOLDQ
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Lowest quartile of coping skills scale scores on the SOLDQ
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Lowest quartile of physical function scores on the SOLDQ
Number of subjects: 3282
Study: 10188712

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9005419

Group type: EXPERIMENTAL
Intervention: Pregnant women with LH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 0
Study: 2072371

Group type: EXPERIMENTAL
Intervention: High carbohydrate meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: No meal
Number of subjects: 8
Study: 6345428

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (300 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac (200 mg daily)
Number of subjects: 40
Study: 30924412

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthoses (AFO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Historical control group (advice to walk at home)
Number of subjects: 15
Study: 30272850

Group type: EXPERIMENTAL
Intervention: Individualised nutrition education with customised dishware and food supplements (mixed nuts and skimmed milk powder)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Multiple micronutrient supplements
Number of subjects: 36

Group type: COMPARATOR
Intervention: Multiple micronutrients plus isolated soy protein supplement
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 26573239

Group type: EXPERIMENTAL
Intervention: Highly filled flowable composite G-aenial Universal Flo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional composite Estelite Sigma Quick
Number of subjects: 32
Study: 25194782

Group type: EXPERIMENTAL
Intervention: lithium plus optimal personalized treatment (OPT)
Number of subjects: 283

Group type: COMPARATOR
Intervention: optimal personalized treatment (OPT) alone
Number of subjects: 283
Study: 22155037

Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (PA) 1.0wt%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (PA) 2.0wt%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (PA) 3.0wt%
Number of subjects: 40

Group type: COMPARATOR
Intervention: PA-free adhesive (Control)
Number of subjects: 40
Study: 21098206

Group type: COMPARATOR
Intervention: Pneumatic dilation (group A, n = 30)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Temporary self-expanding metallic stent (20 mm, group B, n = 30)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Temporary self-expanding metallic stent (25 mm, group C, n = 30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Temporary self-expanding metallic stent (30 mm, group D, n = 30)
Number of subjects: 120
Study: 17390202

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT-4)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 59
Study: 16338914

Group type: EXPERIMENTAL
Intervention: DynaMed (A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (N)
Number of subjects: 52